Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options

Cancer
Sandhya Sharma, Kanti R Rai

Abstract

Within a period of just over a decade, managing chronic lymphocytic leukemia (CLL) has become more effective and yet more challenging than ever before. The important improvement in the treatment of CLL can be ascribed to the availability of many new options, mainly with the development of novel targeted therapies, such as ibrutinib, idelalisib, duvelisib and venetoclax. There are now newer tests that reliably define high-risk patients, and treatment plans can be tailored accordingly. Overall, this indeed is a new era in the treatment of patients with CLL. However, despite this progress, CLL remains an incurable disease and continues to remain challenging. In this brief review, the authors highlight the many great choices available to clinicians who manage patients with CLL and focus on the sequencing of these choices based on the available data.

References

May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthUNKNOWN Minnie Pearl Cancer Research Network
Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexander KröberStephan Stilgenbauer
Feb 3, 2012·Leukemia·S PospisilovaUNKNOWN European Research Initiative on CLL (ERIC)
Mar 8, 2012·Blood·Thorsten ZenzStephan Stilgenbauer
Oct 2, 2012·The Journal of Clinical Investigation·Gianluca GaidanoRiccardo Dalla-Favera
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenChristopher F E Pocock
Oct 11, 2014·Blood·Peter DregerUNKNOWN European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
Dec 8, 2015·The New England Journal of Medicine·Jan A BurgerUNKNOWN RESONATE-2 Investigators
Dec 8, 2015·The New England Journal of Medicine·Andrew W RobertsJohn F Seymour
Nov 18, 2017·International Journal of Epidemiology·Vanessa L Gordon-DseaguRachael Stolzenberg-Solomon
Mar 22, 2018·The New England Journal of Medicine·John F SeymourArnon P Kater
Jan 9, 2019·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

May 31, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P BertuccioE Negri
Apr 16, 2020·Expert Opinion on Pharmacotherapy·Anna Maria FrustaciMarco Montillo
Jul 20, 2020·International Journal of Cancer. Journal International Du Cancer·Fuli FanLeopold Sellner
Jul 25, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Abigail S RobbertzJennifer A Woyach
Jul 17, 2020·Expert Review of Hematology·Tsering Gyalpo LamaSusan O'Brien
Sep 6, 2019·International Journal of Molecular Sciences·Tom HoflandSanne H Tonino
Jan 13, 2021·JCO Global Oncology·Kaladada Ibitrokoemi KoruboSampson Ibekwe Ezeugwu
Jan 12, 2021·Frontiers in Oncology·Hye Na KimYong-Mi Kim
May 15, 2021·Cancer Management and Research·Katarzyna SkórkaKrzysztof Giannopoulos
Jun 4, 2021·Blood·Marcin Kortylewski
May 21, 2021·Clinical Lymphoma, Myeloma & Leukemia·Keren HodSigal Tavor
Aug 6, 2021·Current Opinion in Immunology·Edina Schweighoffer, Victor Lj Tybulewicz
Dec 11, 2021·Leukemia & Lymphoma·María Elena CabreraEstella Matutes
Jan 18, 2022·Leukemia & Lymphoma·Christopher M MelénBjörn Engelbrekt Wahlin

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

© 2022 Meta ULC. All rights reserved